Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: Results of the AHT randomized trial

Journal of Clinical Oncology

Volumn 33, Issue 35, 2015, Pages 4138-4144

  Eeles, Rosalind A ^a   Morden, James P ^a   Gore, Martin ^b   Mansi, Janine ^c   Glees, John ^e,f   Wenczl, Miklos ^k   Williams, Christopher ^g   Kitchener, Henry ^h   Osborne, Richard ⁱ   Guthrie, David ^j   Harper, Peter ^d   Bliss, Judith M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Royal Marsden Hospital   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

^e EPSOM GENERAL HOSPITAL   (United Kingdom)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^h ABERDEEN ROYAL INFIRMARY   (United Kingdom)

ⁱ ADDENBROOKE S HOSPITAL   (United Kingdom)

^j DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

^k Markusovszky Teaching Hospital   (Hungary)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS NORGESTREL; ESTRADIOL; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; COLON CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRACTURE; HEART INFARCTION; HUMAN; HUNGARY; INTENTION TO TREAT ANALYSIS; JEJUNUM CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MEDIASTINUM CANCER; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVARY FUNCTION; OVERALL SURVIVAL; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SECOND CANCER; SPAIN; TRANSIENT ISCHEMIC ATTACK; TUMOR DIFFERENTIATION; UNITED KINGDOM; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GREAT BRITAIN; HORMONE SUBSTITUTION; KAPLAN MEIER METHOD; MEDICATION COMPLIANCE; NEOPLASMS, GLANDULAR AND EPITHELIAL; ODDS RATIO; OVARIAN NEOPLASMS; PREVENTION AND CONTROL; QUALITY OF LIFE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HORMONE REPLACEMENT THERAPY; HUMANS; HUNGARY; KAPLAN-MEIER ESTIMATE; MEDICATION ADHERENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; ODDS RATIO; OVARIAN NEOPLASMS; QUALITY OF LIFE; SPAIN; TREATMENT OUTCOME;

EID: 84957607708     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.60.9719     Document Type: Article

References (29)

1. Ferlay J, Shin HR, Bray F, et al: GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. http://www.globocan.iarc.fr
2. Richelson LS, Wahner HW, Melton LJ, et al: Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 311:1273-1275, 1984
3. Colditz GA, Willett WC, Stampfer MJ, et al: Menopause and the risk of coronary heart disease in women. N Engl J Med 316:1105-1110, 1987
4. Coope J, Thomson JM, Poller L: Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting. BMJ 4:139-143, 1975
5. Horsman A, Gallagher JC, Simpson M, et al: Prospective trial of oestrogen and calcium in postmenopausal women. BMJ 2:789-792, 1977
6. Kuhnel R, Delemarre JF, Rao BR, et al: Correlation of multiple steroid receptors with histological type and grade in human ovarian cancer. Int J Gynecol Pathol 6:248-256, 1987
7. Weiss NS, Lyon JL, Krishnamurthy S, et al: Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 68:95-98, 1982
8. Cramer DW, Hutchison GB, Welch WR, et al: Determinants of ovarian cancer risk, I: Reproductive experiences and family history. J Natl Cancer Inst 71:711-716, 1983
9. Neves-E-Castro M: An analysis of ovarian cancer in the Million Women Study. Gynecol Endocrinol 23:410-413, 2007
10. Mørch LS, Løokkegaard E, Andreasen AH, et al: Hormone therapy and different ovarian cancers: A national cohort study. Am J Epidemiol 175:1234-1242, 2012
11. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Gaitskell K, et al: Menopausal hormone use and ovarian cancer risk: Individual participant meta-analysis of 52 epidemiological studies. Lancet 385:1835-1842, 2015
12. La Vecchia C, Liberati A, Franceschi S: Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 69:1207, 1982
13. Franceschi S, Lavecchia C, Helmrich SP, et al: Risk factors for epithelial ovarian cancer in Italy. Am J Epidemiol 115:714-719, 1982
14. Eeles RA, Tan S, Wiltshaw E, et al: Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302:259-262, 1991
15. Royston P, Parmar MKB: The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med 30:2409-2421, 2011
16. Warwick J, Kehoe S, Earl H, et al: Long-term follow-up of patients with advanced ovarian cancer treated in randomized clinical trials. Br J Cancer 72:1513-1517, 1995
17. Rustin GJS, van der Burg MEL, Griffin CL, et al: Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): A randomised trial. Lancet 376:1155-1163, 2010
18. Guidozzi F, Daponte A: Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 86:1013-1018, 1999
19. Holmberg L, Anderson H: HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: Trial stopped. Lancet 363:453-455, 2004
20. Bebar S, Ursic-Vrscaj M: Hormone replacement therapy after epithelial ovarian cancer treatment. Eur J Gynaecol Oncol 21:192-196, 2000
21. Mascarenhas C, Lambe M, Bellocco R, et al: Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 119:2907-2915, 2006
22. Lee KB, Lee JM, Yoon JH, et al: The safety of tibolone in epithelial ovarian cancer patients. Maturitas 55:156-161, 2006
23. Hein A, Thiel FC, Bayer CM, et al: Hormone replacement therapy and prognosis in ovarian cancer patients. Eur J Cancer Prevention 22:52-58, 2013
24. Topatan S, Yildiz H: Symptoms experienced by women who enter into natural and surgical menopause and their relation to sexual functions. Health Care Women Int 33:525-539, 2012
25. Vavilis D, Chatzigeorgiou K, Goulis D, et al: Hormonal replacement therapy in ovarian cancer survivors: A survey among Greek gynecologists. Eur J Gynaecol Oncol 32:538-541, 2011
26. Gulliver LSM, Hurst PR: Repeat estradiol exposure differentially regulates protein expression patterns for estrogen receptor and E-cadherin in older mouse ovarian surface epithelium: Implications for replacement and adjuvant hormone therapies? Steroids 77:674-685, 2012
27. Holmberg L, Anderson H: HABITS steering and data monitoring committees: HABITS (hormonal replacement therapy after breast cancer) - is it safe? A randomised comparison: Trial stopped. Lancet 363:453-455, 2004
28. Fahlen M, Fornander T, Johansson H, et al: Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 49:52-59, 2013
29. Powles TJ, Eeles R, Ashley S, et al: Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283-290, 2007